CMG Pharmaceutical Co., Ltd. (058820.KQ)
KRW 2600.0
(-0.95%)
KRW 2600.0
(-0.95%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 37.86 Billion KRW | 7.24% |
| 2022 | 37.92 Billion KRW | 19.28% |
| 2021 | 31.79 Billion KRW | 8.17% |
| 2020 | 29.38 Billion KRW | 29.89% |
| 2019 | 22.62 Billion KRW | 1597.78% |
| 2018 | 1.33 Billion KRW | 17.2% |
| 2017 | 1.13 Billion KRW | 2.9% |
| 2016 | 1.1 Billion KRW | 19.35% |
| 2015 | 925.9 Million KRW | 10.07% |
| 2014 | 841.2 Million KRW | 25.66% |
| 2013 | 669.45 Million KRW | 17.22% |
| 2012 | 571.08 Million KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 10.27 Billion KRW | 1250.71% |
| 2024 Q1 | 686.33 Million KRW | -93.3% |
| 2023 Q2 | 10.42 Billion KRW | 3.72% |
| 2023 FY | 40.66 Billion KRW | 7.24% |
| 2023 Q4 | 10.24 Billion KRW | 3.22% |
| 2023 Q1 | 10.05 Billion KRW | -9.17% |
| 2023 Q3 | 9.93 Billion KRW | -4.79% |
| 2022 Q3 | 548.37 Million KRW | 1.94% |
| 2022 FY | 37.92 Billion USD | 19.28% |
| 2022 Q4 | 11.07 Billion KRW | 1918.82% |
| 2022 Q2 | 537.96 Million KRW | -3.83% |
| 2022 Q1 | 559.42 Million KRW | 0.22% |
| 2021 Q1 | 522.02 Million KRW | 7.68% |
| 2021 FY | 31.79 Billion USD | 8.17% |
| 2021 Q2 | 504.59 Million KRW | -3.34% |
| 2021 Q3 | 514.32 Million KRW | 1.93% |
| 2021 Q4 | 558.17 Million KRW | 8.53% |
| 2020 Q3 | 473.54 Million KRW | 9.09% |
| 2020 Q1 | 388.5 Million KRW | -0.59% |
| 2020 Q2 | 434.07 Million KRW | 11.73% |
| 2020 FY | 29.38 Billion USD | 29.89% |
| 2020 Q4 | 484.79 Million KRW | 2.38% |
| 2019 Q2 | 372.95 Million KRW | 9.99% |
| 2019 Q4 | 390.8 Million KRW | 9.62% |
| 2019 Q1 | 339.07 Million KRW | -5.29% |
| 2019 Q3 | 356.52 Million KRW | -4.4% |
| 2019 FY | 22.62 Billion USD | 1597.78% |
| 2018 FY | 1.33 Billion USD | 17.2% |
| 2018 Q4 | 358 Million KRW | 5.84% |
| 2018 Q3 | 338.24 Million KRW | -5.21% |
| 2018 Q2 | 356.85 Million KRW | 27.65% |
| 2018 Q1 | 279.55 Million KRW | -0.19% |
| 2017 Q1 | 267.04 Million KRW | -3.82% |
| 2017 Q2 | 277.36 Million KRW | 3.86% |
| 2017 Q3 | 312.57 Million KRW | 12.7% |
| 2017 FY | 1.13 Billion USD | 2.9% |
| 2017 Q4 | 280.07 Million KRW | -10.4% |
| 2016 FY | 1.1 Billion USD | 19.35% |
| 2016 Q4 | 277.65 Million KRW | -8.37% |
| 2016 Q3 | 303.01 Million KRW | 13.78% |
| 2016 Q2 | 266.3 Million KRW | 3.19% |
| 2016 Q1 | 258.07 Million KRW | 13.02% |
| 2015 Q2 | 238.06 Million KRW | 10.79% |
| 2015 Q1 | 214.88 Million KRW | 2.47% |
| 2015 FY | 925.9 Million USD | 10.07% |
| 2015 Q4 | 228.34 Million KRW | -6.65% |
| 2015 Q3 | 244.61 Million KRW | 2.75% |
| 2014 Q4 | 209.7 Million KRW | -2.7% |
| 2014 Q3 | 215.52 Million KRW | -3.05% |
| 2014 Q2 | 222.3 Million KRW | 14.78% |
| 2014 Q1 | 193.66 Million KRW | 6.11% |
| 2014 FY | 841.2 Million USD | 25.66% |
| 2013 Q1 | 148.02 Million KRW | -1.28% |
| 2013 FY | 669.45 Million USD | 17.22% |
| 2013 Q3 | 173.41 Million KRW | 4.79% |
| 2013 Q2 | 165.49 Million KRW | 11.8% |
| 2013 Q4 | 182.51 Million KRW | 5.25% |
| 2012 Q4 | 149.95 Million KRW | 0.0% |
| 2012 FY | 571.08 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 102.52 Billion KRW | 63.067% |
| Celltrion Pharm, Inc. | 80.93 Billion KRW | 53.215% |
| Huons Global Co., Ltd. | 294.87 Billion KRW | 87.159% |
| DongKook Pharmaceutical Co., Ltd. | 338.16 Billion KRW | 88.802% |
| Enzychem Lifesciences Corporation | 18.7 Billion KRW | -102.448% |
| Humedix Co., Ltd. | 33.04 Billion KRW | -14.596% |
| Boditech Med Inc. | 47.05 Billion KRW | 19.522% |
| EuBiologics Co., Ltd. | 24.95 Billion KRW | -51.709% |
| FutureChem Co.,Ltd | 9.16 Billion KRW | -313.112% |
| Huons Co., Ltd. | 226.14 Billion KRW | 83.256% |
| BNC Korea Co., Ltd. | 25.19 Billion KRW | -50.27% |
| AptaBio Therapeutics Inc. | 16.45 Billion KRW | -130.163% |